MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 533794 | Name: MCU-i4
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

MCU-i4 is a novel negative modulator of the MCU, binding MICU1 and impairing muscle cell growth.

Chemical Structure

MCU-i4
MCU-i4
CAS#371924-24-2

Theoretical Analysis

MedKoo Cat#: 533794

Name: MCU-i4

CAS#: 371924-24-2

Chemical Formula: C23H27N3O2

Exact Mass: 377.2103

Molecular Weight: 377.49

Elemental Analysis: C, 73.18; H, 7.21; N, 11.13; O, 8.48

Price and Availability

Size Price Availability Quantity
25mg USD 90.00 Ready to ship
50mg USD 150.00 Ready to ship
100mg USD 250.00 Ready to ship
200mg USD 450.00 Ready to ship
500mg USD 950.00 Ready to ship
1g USD 1,650.00 Ready to ship
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
MCU-i4; MCUi4; MCU i4;
IUPAC/Chemical Name
Ethyl 4-((4-(diethylamino)phenyl)amino)-6-methylquinoline-3-carboxylate
InChi Key
RIWXBJCWHVMATR-UHFFFAOYSA-N
InChi Code
InChI=1S/C23H27N3O2/c1-5-26(6-2)18-11-9-17(10-12-18)25-22-19-14-16(4)8-13-21(19)24-15-20(22)23(27)28-7-3/h8-15H,5-7H2,1-4H3,(H,24,25)
SMILES Code
O=C(C1=C(NC2=CC=C(N(CC)CC)C=C2)C3=CC(C)=CC=C3N=C1)OCC
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Biological target:
MCU-i4 blocks the IP3-dependent mitochondrial Ca2+-uptake, maintaining the gatekeeping role of their target.
In vitro activity:
For this purpose, this study measured mitochondrial Ca2+ uptake speed in cells permeabilized with digitonin and then perfused with 3 μM Ca2+ in the presence of the active molecules (Figure 2C). MCU-i4 and MCU-i11 decreased mitochondrial Ca2+ uptake speed. These results confirm that the selected compounds impinge directly on the MCU complex activity rather than on Ca2+ release from intracellular stores or on cytosolic [Ca2+]. Reference: Cell Rep. 2020 Feb 18;30(7):2321-2331.e6. https://pubmed.ncbi.nlm.nih.gov/32075766/
In vivo activity:
Both MCU-i4 and MCU-i11 inhibited mitochondrial Ca2+ uptake in myofibers (Figure 5C). Both compounds decreased myotube width (Figure 5D). These data prove the efficacy of MCU-i4 and MCU-i11 ex vivo and indicate that pharmacological modulation of mitochondrial Ca2+ uptake interferes with an essential biological process. Reference: Cell Rep. 2020 Feb 18;30(7):2321-2331.e6. https://pubmed.ncbi.nlm.nih.gov/32075766/
Solvent mg/mL mM
Solubility
DMSO 18.9 50.00
Ethanol 37.8 100.00
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 377.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Di Marco G, Vallese F, Jourde B, Bergsdorf C, Sturlese M, De Mario A, Techer-Etienne V, Haasen D, Oberhauser B, Schleeger S, Minetti G, Moro S, Rizzuto R, De Stefani D, Fornaro M, Mammucari C. A High-Throughput Screening Identifies MICU1 Targeting Compounds. Cell Rep. 2020 Feb 18;30(7):2321-2331.e6. doi: 10.1016/j.celrep.2020.01.081. PMID: 32075766; PMCID: PMC7034061.
In vitro protocol:
1. Di Marco G, Vallese F, Jourde B, Bergsdorf C, Sturlese M, De Mario A, Techer-Etienne V, Haasen D, Oberhauser B, Schleeger S, Minetti G, Moro S, Rizzuto R, De Stefani D, Fornaro M, Mammucari C. A High-Throughput Screening Identifies MICU1 Targeting Compounds. Cell Rep. 2020 Feb 18;30(7):2321-2331.e6. doi: 10.1016/j.celrep.2020.01.081. PMID: 32075766; PMCID: PMC7034061.
In vivo protocol:
1. Di Marco G, Vallese F, Jourde B, Bergsdorf C, Sturlese M, De Mario A, Techer-Etienne V, Haasen D, Oberhauser B, Schleeger S, Minetti G, Moro S, Rizzuto R, De Stefani D, Fornaro M, Mammucari C. A High-Throughput Screening Identifies MICU1 Targeting Compounds. Cell Rep. 2020 Feb 18;30(7):2321-2331.e6. doi: 10.1016/j.celrep.2020.01.081. PMID: 32075766; PMCID: PMC7034061.
1: Di Marco G, Vallese F, Jourde B, Bergsdorf C, Sturlese M, De Mario A, Techer- Etienne V, Haasen D, Oberhauser B, Schleeger S, Minetti G, Moro S, Rizzuto R, De Stefani D, Fornaro M, Mammucari C. A High-Throughput Screening Identifies MICU1 Targeting Compounds. Cell Rep. 2020 Feb 18;30(7):2321-2331.e6. doi: 10.1016/j.celrep.2020.01.081. PMID: 32075766; PMCID: PMC7034061.